×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Proteostasis Therapy CBS PSP
therapeutic
2,566 words
KG: ent-dise-bfd8f32d
2026-03-24
state:published
Contents
Proteostasis Therapy CBS PSP
💊
Therapeutic Info
Name
Proteostasis Therapy CBS PSP
Summary
Comprehensive coverage of proteostasis network dysfunction in CBS PSP
Knowledge Graph
Related Hypotheses (30)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
APOE Isoform Conversion Therapy
Score: 0.44
Heat Shock Protein 70 Disaggregase Amplification
Score: 0.51
Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.48
Circadian-Synchronized Proteostasis Enhancement
Score: 0.58
Cryptic Exon Silencing Restoration
Score: 0.46
Cross-Seeding Prevention Strategy
Score: 0.45
Glycine-Rich Domain Competitive Inhibition
Score: 0.43
VCP-Mediated Autophagy Enhancement
Score: 0.41
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45
Proteostasis Enhancement via APOE Chaperone Targeting
Score: 0.50
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.37
Microglial AIM2 Inflammasome as the Primary Driver of TDP-43
Score: 0.60
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Cell-Type Specific TFEB Modulation
Score: 0.48
Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo
Score: 0.47
Conditional CRISPR Kill Switches for Aberrant Protein Cleara
Score: 0.45
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.68
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
CYP46A1 Overexpression Gene Therapy
Score: 0.63
APOE-Dependent Autophagy Restoration
Score: 0.61
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
PARP1 Inhibition Therapy
Score: 0.58
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Circadian Clock-Autophagy Synchronization
Score: 0.55
Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.55
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Show 25 more
Related Analyses (22)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Show 17 more
Related Experiments (22)
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi
validation · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40
Tau Spreading Network Mapping via Spatial Transcriptomics in
clinical · proposed · Score: 0.40
Trehalose-induced lysosomal changes and TFEB activation
exploratory · proposed · Score: 0.90
Trehalose-induced lysosomal membrane permeabilization and TF
exploratory · proposed · Score: 0.90
Functional validation of trehalose effects on misfolded prot
exploratory · proposed · Score: 0.85
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Selective Vulnerability of Dopaminergic Neurons — Mechanism
validation · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic
validation · proposed · Score: 0.40
Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90
Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Show 17 more
See Also (10)
LX1001 Long-Term Follow-up (NCT05400330) - Gene Therapy
clinical · Pages share 4 hypotheses
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for
clinical · Pages share 4 hypotheses
BEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 4 hypotheses
UPenn Observational Research Repository (NCT04715399)
clinical · Pages share 3 hypotheses
remternetug-anti-amyloid-alzheimers
clinical_trial · Pages share 3 hypotheses
ALA-enriched Nutrition for APOE4 Carriers with MCI (NCT
clinical · Pages share 3 hypotheses
A Phase 2 Double-Blind, Randomized, Placebo-Controlled
clinical · Pages share 3 hypotheses
nct05508789
clinical_trial · Pages share 3 hypotheses
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-
clinical · Pages share 3 hypotheses
Adipose-Derived Mesenchymal Stem Cell Therapy for Early
clinical · Pages share 3 hypotheses
Show 5 more